Download MendeleyDiscovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.
Michaelides, I.N., Collie, G.W., Borjesson, U., Vasalou, C., Alkhatib, O., Barlind, L., Cheung, T., Dale, I.L., Embrey, K.J., Hennessy, E.J., Khurana, P., Koh, C.M., Lamb, M.L., Liu, J., Moss, T.A., O'Neill, D.J., Phillips, C., Shaw, J., Snijder, A., Storer, R.I., Stubbs, C.J., Han, F., Li, C., Qiao, J., Sun, D.Q., Wang, J., Wang, P., Yang, W.(2023) J Med Chem 66: 8782-8807
- PubMed: 37343272
- DOI: https://doi.org/10.1021/acs.jmedchem.3c00401
- Primary Citation of Related Structures:
8OUU, 8OUV, 8OV7, 8OVZ, 8OW3, 8OWG - PubMed Abstract:
Recent clinical reports have highlighted the need for wild-type (WT) and mutant dual inhibitors of c-MET kinase for the treatment of cancer. We report herein a novel chemical series of ATP competitive type-III inhibitors of WT and D1228V mutant c-MET. Using a combination of structure-based drug design and computational analyses, ligand 2 was optimized to a highly selective chemical series with nanomolar activities in biochemical and cellular settings. Representatives of the series demonstrate excellent pharmacokinetic profiles in rat in vivo studies with promising free-brain exposures, paving the way for the design of brain permeable drugs for the treatment of c-MET driven cancers.
Organizational Affiliation:
Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.
